[go: up one dir, main page]

MX2023010750A - Nuevos usos de derivados de piperidinil-indol. - Google Patents

Nuevos usos de derivados de piperidinil-indol.

Info

Publication number
MX2023010750A
MX2023010750A MX2023010750A MX2023010750A MX2023010750A MX 2023010750 A MX2023010750 A MX 2023010750A MX 2023010750 A MX2023010750 A MX 2023010750A MX 2023010750 A MX2023010750 A MX 2023010750A MX 2023010750 A MX2023010750 A MX 2023010750A
Authority
MX
Mexico
Prior art keywords
piperidinyl
indole derivatives
novel uses
treatment
patients suffering
Prior art date
Application number
MX2023010750A
Other languages
English (en)
Inventor
Jörg Eder
Richard Alexander Harrison
Boerje Haraldsson
Anna Svenja Schubart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2023010750A publication Critical patent/MX2023010750A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere al uso novedoso de ciertos derivados de piperidinil-indol en el tratamiento de pacientes que padecen enfermedades o trastornos renales, y en particular, para el tratamiento de pacientes que padecen C3G (glomerulopatía C3) e IgAN (nefropatía por IgA).
MX2023010750A 2017-08-31 2020-02-26 Nuevos usos de derivados de piperidinil-indol. MX2023010750A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17188870 2017-08-31

Publications (1)

Publication Number Publication Date
MX2023010750A true MX2023010750A (es) 2023-09-20

Family

ID=59745840

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020002185A MX2020002185A (es) 2017-08-31 2018-08-30 Nuevos usos de derivados de piperidinil-indol.
MX2023010751A MX2023010751A (es) 2017-08-31 2020-02-26 Nuevos usos de derivados de piperidinil-indol.
MX2023010750A MX2023010750A (es) 2017-08-31 2020-02-26 Nuevos usos de derivados de piperidinil-indol.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2020002185A MX2020002185A (es) 2017-08-31 2018-08-30 Nuevos usos de derivados de piperidinil-indol.
MX2023010751A MX2023010751A (es) 2017-08-31 2020-02-26 Nuevos usos de derivados de piperidinil-indol.

Country Status (22)

Country Link
US (3) US11723901B2 (es)
EP (3) EP3675854B1 (es)
JP (3) JP6754919B1 (es)
KR (3) KR20240111007A (es)
CN (5) CN117338782A (es)
AU (1) AU2018326768B2 (es)
BR (1) BR112020003737A2 (es)
CA (1) CA3073346A1 (es)
CL (1) CL2020000483A1 (es)
DK (1) DK3675854T3 (es)
ES (1) ES3022885T3 (es)
FI (2) FI3675854T3 (es)
HR (2) HRP20251596T1 (es)
HU (1) HUE071118T2 (es)
IL (1) IL272888B2 (es)
LT (2) LT4393545T (es)
MX (3) MX2020002185A (es)
PL (1) PL3675854T3 (es)
PT (2) PT3675854T (es)
RS (1) RS66635B1 (es)
SI (1) SI3675854T1 (es)
WO (1) WO2019043609A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002185A (es) 2017-08-31 2020-07-14 Novartis Ag Nuevos usos de derivados de piperidinil-indol.
CN114828856B (zh) * 2019-12-19 2024-11-05 大鹏药品工业株式会社 以稠合嘧啶化合物为有效成分的治疗剂
CA3180829A1 (en) 2020-05-18 2021-11-25 Novartis Ag Crystalline form of lnp023
EP4194449A4 (en) * 2020-08-07 2024-03-20 Shanghai Meiyue Biotech Development Co., Ltd. Heterocyclic compound, preparation method therefor and use thereof
AU2021323300B2 (en) * 2020-08-07 2025-12-18 Shanghai Meiyue Biotech Development Co., Ltd. Complement factor B inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof
CA3203320A1 (en) * 2020-12-30 2022-07-07 Xin Li Nitrogen-containing bridged heterocyclic compound, preparation method therefor, and medical use thereof
US20240109861A1 (en) * 2020-12-30 2024-04-04 Medshine Discovery Inc. Series of piperidine-substituted benzoic acid compounds, and use thereof
MX2023013148A (es) * 2021-05-07 2023-11-28 Novartis Ag Iptacopan para el tratamiento del sindrome uremico hemolitico atipico.
US20240383917A1 (en) * 2021-08-18 2024-11-21 Xizang Haisco Pharmaceutical Co., Ltd. Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
TW202334121A (zh) * 2021-10-27 2023-09-01 美商翰森生物有限責任公司 哌啶基吲哚衍生物、其製備方法及醫藥用途
WO2023139534A1 (en) * 2022-01-24 2023-07-27 Novartis Ag Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
CA3242815A1 (en) * 2022-01-26 2023-08-03 Shanghai Meiyue Biotech Development Co., Ltd. Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
WO2023237041A1 (zh) * 2022-06-10 2023-12-14 正大天晴药业集团股份有限公司 双环取代的芳香羧酸酯类化合物
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
CN119403797A (zh) * 2022-06-30 2025-02-07 江苏恒瑞医药股份有限公司 一种含氮桥杂环衍生物的可药用盐、晶型及其制备方法
EP4584255A1 (en) * 2022-09-10 2025-07-16 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof
KR20250103768A (ko) * 2022-11-11 2025-07-07 상하이 이셩 바이오파마슈티컬 컴퍼니 리미티드 피리딘 치환 벤조산계 화합물, 이의 약학 조성물 및 용도
WO2024141011A1 (zh) * 2022-12-31 2024-07-04 深圳晶泰科技有限公司 补体因子b抑制剂及其药物组合物和应用
WO2025021158A1 (zh) * 2023-07-26 2025-01-30 上海美悦生物科技发展有限公司 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
CN104640855B (zh) * 2012-06-28 2017-08-29 诺华股份有限公司 补体途经调节剂及其用途
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
AU2016375183B2 (en) 2015-12-23 2021-01-21 eleva GmbH Polypeptides for inhibiting complement activation
MX2020002185A (es) 2017-08-31 2020-07-14 Novartis Ag Nuevos usos de derivados de piperidinil-indol.
CA3180829A1 (en) 2020-05-18 2021-11-25 Novartis Ag Crystalline form of lnp023
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors

Also Published As

Publication number Publication date
RU2020111788A (ru) 2021-09-30
CN117398384A (zh) 2024-01-16
DK3675854T3 (da) 2025-04-07
MX2020002185A (es) 2020-07-14
CN117338783A (zh) 2024-01-05
US11723901B2 (en) 2023-08-15
JP2020193222A (ja) 2020-12-03
CN117338782A (zh) 2024-01-05
PL3675854T3 (pl) 2025-05-19
KR20200047540A (ko) 2020-05-07
US12285422B2 (en) 2025-04-29
LT4393545T (lt) 2026-01-12
EP3675854A1 (en) 2020-07-08
KR102497487B1 (ko) 2023-02-08
US20220152011A1 (en) 2022-05-19
IL272888A (en) 2020-04-30
JP7297016B2 (ja) 2023-06-23
KR20230024432A (ko) 2023-02-20
IL272888B1 (en) 2023-09-01
AU2018326768A1 (en) 2020-02-06
EP3675854B1 (en) 2025-01-22
ES3022885T3 (en) 2025-05-29
US20250195493A1 (en) 2025-06-19
HRP20251596T1 (hr) 2026-01-30
EP4647121A2 (en) 2025-11-12
FI3675854T3 (fi) 2025-04-07
EP4393545B1 (en) 2025-10-08
US20200338059A1 (en) 2020-10-29
RU2020111788A3 (es) 2021-12-28
JP2021181471A (ja) 2021-11-25
BR112020003737A2 (pt) 2020-09-01
IL272888B2 (en) 2024-01-01
FI4393545T3 (fi) 2026-01-14
RS66635B1 (sr) 2025-04-30
EP4393545A2 (en) 2024-07-03
EP4393545A3 (en) 2024-09-25
HUE071118T2 (hu) 2025-08-28
CA3073346A1 (en) 2019-03-07
CN111032042A (zh) 2020-04-17
PT3675854T (pt) 2025-04-04
JP2020529466A (ja) 2020-10-08
AU2018326768B2 (en) 2021-07-29
CL2020000483A1 (es) 2020-09-04
HRP20250386T1 (hr) 2025-05-23
KR20240111007A (ko) 2024-07-16
JP6754919B1 (ja) 2020-09-16
CN117338781A (zh) 2024-01-05
JP6929425B2 (ja) 2021-09-01
KR102682887B1 (ko) 2024-07-08
MX2023010751A (es) 2023-09-20
LT3675854T (lt) 2025-04-25
PT4393545T (pt) 2025-12-23
WO2019043609A1 (en) 2019-03-07
SI3675854T1 (sl) 2025-05-30

Similar Documents

Publication Publication Date Title
MX2023010750A (es) Nuevos usos de derivados de piperidinil-indol.
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2019268063A1 (en) Compositions for modulating sod-1 expression
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PH12018500057A1 (en) Substituted oxopyridine derivatives
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MY150285A (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use
EP4534092A3 (en) Compositions and methods for modulating pkk expression
PH12015501806B1 (en) Novel benzopyran kinase modulators
NZ737399A (en) Ccr2 modulators
TW201613636A (en) Methods of treating Alzheimer's Disease
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2015016741A (es) Inhibidores de pi3 cinasa delta y gama selectivos duales.
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2017003897A (es) Derivados estabilizados de adrenomedulina y uso de los mismos.
PH12017501872A1 (en) Methods of treating diseases
HK1213175A1 (zh) Tspo介导的疾病和/或病症的治疗和/或预防
MX2017007676A (es) Nuevos compuestos.
WO2015155680A3 (en) Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors
EP4599886A3 (en) Hydrocortisone acetate suppository formulation for use in treating inflammatory bowel disease
PH12018501045A1 (en) Treatment of retinal degeneration using progenitor cells